RSV vaccine study for stem cell and CAR-T therapy patients
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial tests how well the RSV vaccine works in people who have had a stem cell transplant or CAR-T therapy for blood cancer. It will help understand if the vaccine protects you against RSV, a common respiratory virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a blood cancer diagnosis.
- You have received a stem cell transplant or CAR-T therapy.
- You agree to give blood samples before vaccination, and again at four weeks and six months after.
- Your insurance covers the RSV vaccine.
- You have not had a severe allergic reaction to the RSV vaccine before.
- You have not received intravenous immunoglobulin (IVIG) for low antibody levels in the last six months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.
This study tests a new RSV vaccine designed to protect adults with chronic health conditions from severe RSV disease (a respiratory infection). Researchers will monitor how safe the vaccine is and how well your immune system responds to it.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This study tests how your body's immune system responds to a new respiratory syncytial virus (RSV) vaccine. RSV is a common virus that causes respiratory infections, especially in older adults. The vaccine may help protect you from RSV disease.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.